@paulg: It was the best of times, it was the worst of times.
Summary
Derek Thompson highlights recent medical breakthroughs including an effective GLP-1 drug from Eli Lilly and a promising new pancreatic cancer drug from Revolution Medicines.
View Cached Full Text
Cached at: 06/01/26, 01:03 AM
It was the best of times, it was the worst of times.
Derek Thompson (@DKThomp): This has quietly been a miracle month in medicine.
In the last 5 weeks we’ve got news on:
- retatrutide, the triple agonist GLP-1 from Lilly, basically melting fat and body-wide inflammation at record levels
- RevMed’s new pancreatic cancer drug showing unprecedented
Similar Articles
In 2040 which current medical practices will seem barbaric?
The article speculates on how future advancements in math, physics, chemistry, and biology could make current medical practices appear barbaric by 2040.
Launch HN: RonanRX (YC S26) – Personalized Peptides and GLP-1s
RonanRx offers personalized GLP-1 treatments with physician oversight and compounding pharmacies, focusing on tailored dosing and support for side effects.
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The FDA has approved Rasonque (daraxonrasib), a first-in-class RAS inhibitor, for the treatment of metastatic pancreatic cancer, demonstrating improved overall survival in clinical trials.
HealMed: Multilingual Evaluation of Large Language Models in Medicine
HealMed is an expert-reviewed benchmark for evaluating large language models in medicine across nine languages, developed by medical experts to assess multilingual performance in clinical tasks.
What Can Artificial Intelligence Learn from Medicine? Generative Analogies and Reliable Machine Learning Systems
The paper develops a generative analogy between clinical translation in medicine and building reliable machine learning systems, proposing a new form of ML reliabilism based on reliabilist epistemic warrants.